Altium Capital Management’s Pardes Biosciences PRDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-253,000
Closed -$1.83M – 145
2022
Q1
$1.83M Buy
253,000
+53,000
+27% +$521K 0.61% 61
2021
Q4
$3.27M Hold
200,000
– – 0.9% 44
2021
Q3
$1.99M Hold
200,000
– – 0.52% 72
2021
Q2
$2M Hold
200,000
– – 0.46% 85
2021
Q1
$1.99M Buy
+200,000
New +$2.07M 0.55% 77

Other funds holding PRDS

Altium Capital Management's PRDS Position: Q2 2022 in Review

Altium Capital Management sold out of Pardes Biosciences (PRDS) in Q2 2022, closing a stake of 253,000 shares — an estimated $1.83M sold.

Altium Capital Management first reported a position in PRDS in Q1 2021 and held it in 5 quarters. The position peaked at $3.27M in Q4 2021. 69 funds tracked by Wall St. Rank hold PRDS as of Q2 2022.

  • Altium Capital Management reported no remaining Pardes Biosciences position as of Q2 2022 after selling out during the quarter.
  • Altium Capital Management sold 253,000 Pardes Biosciences shares in Q2 2022, an estimated $1.83M.
  • Altium Capital Management first reported a position in Pardes Biosciences in Q1 2021 and held it in 5 quarters.
  • Altium Capital Management's Pardes Biosciences position peaked at $3.27M in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Pardes Biosciences as of Q2 2022.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.